{
  "id": "64040d73201352f04a000010",
  "type": "yesno",
  "question": "Can Efgartigimod be used for myasthenia gravis?",
  "ideal_answer": "Yes. Efgartigimod is effective, approved and can be used for myasthenia gravis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35639288",
    "http://www.ncbi.nlm.nih.gov/pubmed/34146511",
    "http://www.ncbi.nlm.nih.gov/pubmed/35179720"
  ],
  "snippets": [
    {
      "text": "Efgartigimod is an FcRn inhibitor recently approved for MG treatment, and rozanolixizumab, nipocalimab and batoclimab are other agents in clinical trial development. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35639288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efgartigimod (efgartigimod alfa-fcab, Vyvgart\u2122) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. In December 2021, intravenous efgartigimod received its first approval in the USA for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35179720",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35179720",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Efgartigimod was well tolerated and efficacious in patients with generalised myasthenia gravis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34146511",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}